Pfizer (PFE) Received its Third Buy in a Row

After Deutsche Bank and Morgan Stanley gave Pfizer (NYSE: PFE) a Buy rating last month, the company received another Buy, this time from BMO Capital. Analyst Alex Arfaei maintained a Buy rating on Pfizer today and set a price target of $47. The company’s shares opened today at $42.50, close to its 52-week high of $42.80.

According to, Arfaei is a 4-star analyst with an average return of 7.6% and a 71.0% success rate. Arfaei covers the Healthcare sector, focusing on stocks such as Merck & Company, Eli Lilly & Co, and Bristol Myers.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Pfizer with a $47 average price target, implying a 10.6% upside from current levels. In a report issued on September 6, Cowen & Co. also maintained a Buy rating on the stock with a $48 price target.


See today’s analyst top recommended stocks >>

Pfizer’s market cap is currently $248.6B and has a P/E ratio of 11.37. The company has a Price to Book ratio of 3.56.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.